Track CJC‑1295 in Peptimes™
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH): its first 29 amino acids with four substitutions, plus a lysine carrying a maleimidopropionyl group, the drug affinity complex (DAC), which binds to albumin. (Source: FDA.)
Is CJC-1295 FDA-approved?
No. CJC-1295 isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.
CJC-1295
Also: CJC-1295 with DAC, DAC:GRF, Drug Affinity Complex GRF, CJC1295
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- Subcutaneous
- Updated
- 1 Nov 2026
US regulatory status
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In humans
Two randomized, double-blind, placebo-controlled trials in healthy adults aged 21 to 61: CJC-1295 raised blood levels of growth hormone and IGF-1 compared with before treatment.
Source: PMID 16352683, checked 1 Nov 2026
How to track it in Peptimes
Add CJC-1295 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.
- Logging: the amount you took and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell CJC-1295 or any other compound.
More sources
- FDA, Pharmacy Compounding Advisory Committee briefing document, 4 Dec 2024, checked 1 Nov 2026: what CJC-1295 with DAC is, and that none of the CJC-1295 substances is a component of an FDA-approved drug.
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks, checked 1 Nov 2026: CJC-1295 is listed among substances previously in Category 2 whose nominations were withdrawn.
- FDA, Global Substance Registration System, CJC-1295, checked 1 Nov 2026: its sequence and the name CJC1295.
- NIH, ClinicalTrials.gov, NCT00267527, checked 1 Nov 2026: a Phase 2 study of CJC-1295, terminated.